Sun Pharma Posts 26% Profit Jump and ₹5 Dividend How Innovation Is Reshaping India's Largest Pharma Company

Sun Pharma posted a consolidated net profit of ₹2,714 crore for Q4 FY26 up 26.2% YoY. Revenue grew 13.6% to ₹14,559.8 crore. The board proposed a final dividend of ₹5 per share taking total FY26 dividend to ₹16 per share. Net profit → ₹2,714 crore (up 26.2% YoY) Innovative medicines → $354 million (up 20.1% YoY) India market share → up from 8.1% to 8.4% Most Indian pharma companies depend heavily on generic drugs copies of existing medicines sold at lower prices. Sun Pharma is different. It is actively shifting toward innovative medicines new patented drugs that command premium pricing and face less competition. Global innovative medicines grew 20.1% YoY to $354 million even as the US generics business declined 1.1%. This shift is deliberate and powerful. Innovative medicines have higher margins, longer product lifecycles and stronger pricing power than generics. India formulations remained Sun Pharma's largest market at 33.2% of total sales. Growing 14.8% in a competitive market while also increasing market share from 8.1% to 8.4% shows Sun Pharma is not just growing it is winning market share from competitors. Track the innovative medicines pipeline new launches in this segment will drive future margin expansion. Also watch US generics recovery as pricing pressure eases in coming quarters. $SUNPHARMA Sun Pharma's 26% profit jump taught me that pharma companies shifting from generic drugs to innovative medicines unlock higher margins and pricing power and this shift directly pressures peers like Cipla $CIPLA and Dr Reddy's $DRREDDY who still depend heavily on US generics, making it essential to track each pharma company's revenue mix between generics and innovation before comparing or investing in any pharma stock.